2019
DOI: 10.1093/annonc/mdz246.052
|View full text |Cite
|
Sign up to set email alerts
|

RAS mutant allele fraction in plasma predicts benefit to anti-angiogenic based first-line treatment in metastatic colorectal cancer

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles